Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Vanda Pharmaceuticals (VNDA) Leases (2019 - 2025)

Vanda Pharmaceuticals' Leases history spans 7 years, with the latest figure at $7.3 million for Q4 2025.

  • On a quarterly basis, Leases rose 48.55% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 48.55% increase, with the full-year FY2025 number at $7.3 million, up 48.55% from a year prior.
  • Leases hit $7.3 million in Q4 2025 for Vanda Pharmaceuticals, up from $4.4 million in the prior quarter.
  • Over the last five years, Leases for VNDA hit a ceiling of $10.2 million in Q1 2021 and a floor of $4.4 million in Q3 2025.
  • Historically, Leases has averaged $7.4 million across 5 years, with a median of $7.6 million in 2023.
  • Biggest five-year swings in Leases: tumbled 30.41% in 2024 and later skyrocketed 48.55% in 2025.
  • Tracing VNDA's Leases over 5 years: stood at $9.3 million in 2021, then dropped by 9.4% to $8.4 million in 2022, then decreased by 15.44% to $7.1 million in 2023, then tumbled by 30.41% to $4.9 million in 2024, then skyrocketed by 48.55% to $7.3 million in 2025.
  • Business Quant data shows Leases for VNDA at $7.3 million in Q4 2025, $4.4 million in Q3 2025, and $4.8 million in Q2 2025.